Program Schedule

1068
Vaccine Coverage at Milestone Ages among Infants in the United States, 2009-2012

Session: Poster Abstract Session: Vaccines: Knowledge, Attitudes, Coverage, Outcomes, Safety
Friday, October 10, 2014
Room: The Pennsylvania Convention Center: IDExpo Hall BC
Background:

The coverage rate for rotavirus vaccine (RV) in the U.S., as assessed at 19 to 35 months of age, is lower than that for other vaccines, such as pneumococcal conjugate vaccine (PCV) and diphtheria, tetanus, and acellular pertussis vaccine (DTaP). RV differs from these other vaccines, however, in that administration at or beyond 8 months of age is not recommended. It is important to determine if the discrepancy in coverage rates arises during the first 6 months of life, when RV is being given along with DTaP and PCV, or if it arises after 8 months, when there is opportunity for catch-up dosing of DTaP and PCV but not for RV.

Methods:

The MarketScan Commercial database was used to examine vaccination coverage for infants born between January 1, 2009 and May 31, 2012 and had at least 13 months of continuous enrollment in their respective health plans. Current Procedural Terminology (CPT) codes were used to identify vaccines administered as of milestone ages (3, 5, 7, 8, 10, and 13 months). Coverage was computed as the proportion of all infants eligible for vaccination according to the recommended schedule who had received the given vaccines. Coverage rates were stratified by variables such as gender and year of birth, among others.

Results:

Of 392,160 eligible infants, coverage for the first dose at 3 months of age was 76%, 84% and 80% for RV, DTaP, and PCV respectively. At 7 months, coverage for the last dose of RV (dose 2 or 3, depending on product) and for 3 doses of DTaP and PCV, respectively, was 65%, 71% and 67%. At 13 months, the respective coverage rates were 69%, 81% and 82%. We observed an increase in coverage for each vaccine over the 4 study years, with the highest rate in 2012; in that year, coverage for all 3 vaccines was similar at 7 months of age, but differences were pronounced at 13 months of age (Table).

Vaccine

Vaccine Coverage in 2012

 

3 months

5 months

7 months

8 months

13 months

RV

80%

75%

69%

73%

73%

PCV

82%

76%

69%

75%

84%

DTaP

86%

80%

73%

78%

83%

Note: Vaccine coverage  is 1 dose at 3 months, 2 doses at 5 months and 3 doses (2 or 3 doses of RV) at 7, 8 and 13 months

Conclusion:
Coverage for RV is similar to DTaP and PCV at milestone ages of 3, 5, and 7 months. The observation of higher coverage rates for DTaP and PCV at 13 months of age is probably due to catch-up opportunities for these vaccines but not for RV.

Berhanu Gebremeskel, MD, MPH1, Dongmu Zhang, PhD2, Michelle Goveia, MD3, Gary S. Marshall, MD4 and Megan O'brien, PhD, MPH2, (1)Epidemiology, Rutgers, the State University of New Jersey, Philadelphia, PA, (2)Global Health Outcomes, Merck, West Point, PA, (3)Medical Affairs, Merck, West Point, PA, (4)Pediatrics, University of Louisville School of Medicine, Louisville, KY

Disclosures:

B. Gebremeskel, Merck &Co., Inc. : Post-doc fellow , Fellowship funded through Merck &Co., Inc.

D. Zhang, Merck: Employee, Salary

M. Goveia, Merck: Employee and Shareholder, Salary

G. S. Marshall, Merck: Investigator, Research grant and Research support

M. O'brien, Merck: Employee and Shareholder, Salary

Findings in the abstracts are embargoed until 12:01 a.m. EDT, Oct. 8th with the exception of research findings presented at the IDWeek press conferences.

Sponsoring Societies:

© 2014, idweek.org. All Rights Reserved.

Follow IDWeek